PT  - JOURNAL ARTICLE
AU  - Vinall, Maria
ED  - Nishimoto, Norihiro
TI  - Efficacy and Safety of Tocilizumab in Monotherapy, an Anti-II-6 Receptor Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis: Results from a 24 Week Double-Blind Phase III Study
DP  - 2006 Oct 01
TA  - MD Conference Express
PG  - 14--14
VI  - 6
IP  - 3
4099  - http://mdc.sagepub.com/content/6/3/14.1.short
4100  - http://mdc.sagepub.com/content/6/3/14.1.full
AB  - The efficacy and safety of tocilizumab, an anti-IL-6 receptor monoclonal antibody, was examined as a monotherapy in patients with active RA who had inadequate responses to MTX. In this Japanese study, RA patients previously treated with MTX received either tocilizumab 8 mg/kg every 4 weeks + a MTX placebo (tocilizumab group) or a tocilizumab placebo + MTX 8 mg/week (MTX group) for 24 weeks.